Next Article in Journal / Special Issue
Liposome-Based Adjuvants for Subunit Vaccines: Formulation Strategies for Subunit Antigens and Immunostimulators
Previous Article in Journal
Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug–Drug Interactions
Article Menu

Export Article

Open AccessReview
Pharmaceutics 2016, 8(1), 6; doi:10.3390/pharmaceutics8010006

Development of Liposomal Ciprofloxacin to Treat Lung Infections

Aradigm Corp., Hayward, CA 94545, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Natasa Skalko-Basnet
Received: 2 January 2016 / Revised: 22 February 2016 / Accepted: 23 February 2016 / Published: 1 March 2016
(This article belongs to the Special Issue Liposome Technologies 2015)

Abstract

Except for management of Pseudomonas aeruginosa (PA) in cystic fibrosis, there are no approved inhaled antibiotic treatments for any other diseases or for infections from other pathogenic microorganisms such as tuberculosis, non-tuberculous mycobacteria, fungal infections or potential inhaled biowarfare agents including Francisella tularensis, Yersinia pestis and Coxiella burnetii (which cause pneumonic tularemia, plague and Q fever, respectively). Delivery of an antibiotic formulation via the inhalation route has the potential to provide high concentrations at the site of infection with reduced systemic exposure to limit side effects. A liposomal formulation may improve tolerability, increase compliance by reducing the dosing frequency, and enhance penetration of biofilms and treatment of intracellular infections. Two liposomal ciprofloxacin formulations (Lipoquin® and Pulmaquin®) that are in development by Aradigm Corporation are described here. View Full-Text
Keywords: liposomes; formulation; ciprofloxacin; lung infection; cystic fibrosis; bronchiectasis; non-tuberculous mycobacteria; inhalation delivery liposomes; formulation; ciprofloxacin; lung infection; cystic fibrosis; bronchiectasis; non-tuberculous mycobacteria; inhalation delivery
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary material

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Cipolla, D.; Blanchard, J.; Gonda, I. Development of Liposomal Ciprofloxacin to Treat Lung Infections. Pharmaceutics 2016, 8, 6.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top